Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.

ABSTRACT:

Introduction

To evaluate counterregulatory hormonal responses during a hypoglycemic clamp with tirzepatide.

Methods

Participants with type 2 diabetes (N=42) were randomized to tirzepatide (15 mg) or placebo for 12 weeks in a crossover design, with a wash-out period of 8-10 weeks. The primary objective was the change in glucagon response during clamp-induced hypoglycemia from plasma glucose (PG) 100 mg/dL to nadir PG (45 mg/dL). Secondary measures were changes in responses of other counterregulatory hormones during clamp-induced hypoglycemia. Time to recovery from the nadir to 72 mg/dL and hypoglycemic symptom scores using the 7-point Edinburgh Hypoglycemia Symptom scale were also assessed.

Results

At 12 weeks, HbA1c change from baseline was -1.5% with tirzepatide vers

SUBMITTER: Pieber TR 

PROVIDER: S-EPMC12436105 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature